Andrographolide‐loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell line

[1]  A. Bilia,et al.  Albumin Nanoparticles for Brain Delivery: A Comparison of Chemical versus Thermal Methods and in vivo Behavior , 2016, ChemMedChem.

[2]  A. Bilia,et al.  Development of Blood-Brain Barrier Permeable Nanoparticles as Potential Carriers for Salvianolic Acid B to CNS , 2016, Planta Medica.

[3]  Artem Cherkasov,et al.  Towards Better BBB Passage Prediction Using an Extensive and Curated Data Set , 2015, Molecular Informatics.

[4]  Francisco Melo,et al.  Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo. , 2015, The Biochemical journal.

[5]  P. Chaudhari,et al.  Enhanced hepatoprotective activity of andrographolide complexed with a biomaterial , 2015, Drug delivery.

[6]  N. Inestrosa,et al.  Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 mice , 2014, Molecular Neurodegeneration.

[7]  J. Kreuter,et al.  Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? , 2014, Advanced drug delivery reviews.

[8]  H. Wei,et al.  Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity. , 2013, Journal of pharmaceutical sciences.

[9]  A. Moses,et al.  Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood–brain barrier model for drug permeability studies , 2013, Fluids and Barriers of the CNS.

[10]  T. Kanda,et al.  Stable human brain microvascular endothelial cell line retaining its barrier‐specific nature independent of the passage number , 2013 .

[11]  M. Masserini.  Nanoparticles for Brain Drug Delivery , 2013, ISRN biochemistry.

[12]  J. Kreuter.  Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB) , 2013, Journal of microencapsulation.

[13]  P. Couraud,et al.  The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.

[14]  Ahmed O Elzoghby,et al.  Albumin-based nanoparticles as potential controlled release drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Barbara Luppi,et al.  Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[17]  A. Mukherjee,et al.  Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations , 2010, International journal of nanomedicine.

[18]  Su Jing Chan,et al.  Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia , 2010, British journal of pharmacology.

[19]  B. Luppi,et al.  New environmental sensitive system for colon-specific delivery of peptidic drugs. , 2008, International journal of pharmaceutics.

[20]  P. Artursson,et al.  Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.

[21]  P. Giunchedi,et al.  Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. , 2006, International journal of pharmaceutics.

[22]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Bin Liu,et al.  Andrographolide Reduces Inflammation-Mediated Dopaminergic Neurodegeneration in Mesencephalic Neuron-Glia Cultures by Inhibiting Microglial Activation , 2004, Journal of Pharmacology and Experimental Therapeutics.

[24]  J. Irache,et al.  Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[26]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[27]  Alex Avdeef,et al.  In vitro trans-monolayer permeability calculations: often forgotten assumptions. , 2003, Drug discovery today.

[28]  J. Kreuter.  Transport of Drugs Across the Blood-Brain Barrier by Nanoparticles , 2002 .

[29]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[30]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[31]  J. Irache,et al.  Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  K. Langer,et al.  Desolvation process and surface characterisation of protein nanoparticles. , 2000, International journal of pharmaceutics.

[33]  R. Alyautdin,et al.  Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles , 1997 .

[34]  J. Cooper,et al.  Molecular sieving characteristics of the cultured endothelial monolayer , 1987, Journal of cellular physiology.